Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

Triple-Negative Breast Cancer Clinical Trial

Official title:

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02993094
• Other study ID #: AGMT_MBC-10 (X16087)
• Secondary ID: 2016-001421-13
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: November 21, 2016
• Est. completion date: August 15, 2020

Study information

• Verified date: November 2020
• Source: Arbeitsgemeinschaft medikamentoese Tumortherapie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label phase I/II study for patients with advanced (locally advanced inoperable or metastatic) triple-negative breast cancer progressing after first-line therapy receiving ixazomib on days 1, 8, and 15 in combination with carboplatin on days 1, 8, and 15. Cycles will be repeated every four weeks.

Description:

The phase I part of this study uses an alternate dose escalation accelerated titration design. In the accelerated dose-escalation phase a single-patient cohort per dose level will be enrolled, until one dose limiting toxicity (DLT) or 2 moderate toxicities are observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.

DLTs are defined as inability to deliver the drug combination of ixazomib and carboplatin due to drug related toxicity.

The maximum-administered dose (MAD) is defined as the dose at which DLT occur in at least two of six patients treated at that dose level. The dose just below the MAD is considered the maximum-tolerated dose (MTD), providing that DLT is observed in fewer than two of six treated patients (or fewer than one third if more than six patients will be treated) at that dose level. Determination of MAD and MTD is based on DLT observed during the first treatment cycle.

Phase II:

After establishing MTD in phase I, accrual continues to evaluate the efficacy and safety of the combination. A total of 41 patients will be included (patients enrolled in the phase I part within the conventional dose escalation phase at the dose level considered as the MTD may be included).

All subjects will continue on study drugs until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 31
• Est. completion date: August 15, 2020
• Est. primary completion date: August 15, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Metastatic or locally advanced (without curative loco-regional treatment options with curative intention) adenocarcinoma of the breast, histologically confirmed

• Triple-negative subtype defined as the absence of staining for estrogen receptor (IHC <1%), progesterone receptor (IHC <1%) and HER2/neu (IHC 1+ or ISH ratio of < 2.0 between Her2 gene copy number and centromere of chromosome 17 or a copy number of 4 or less)

• Signed informed consent prior to any study-specific procedure, with the understanding that consent may be withdrawn at any time without prejudice to future medical care

• Female patients, age = 18 years

• At least one prior line of chemotherapy for metastatic or locally advanced disease or disease progression within 12 months of completion of adjuvant chemotherapy

• Documented disease progression

• At least one measurable lesion according to RECIST 1.1 criteria

• Life expectancy of at least 12 weeks

• Performance status ECOG 0-2

• Adequate left ventricular ejection fraction at baseline, defined as LVEF = 50% by either echocardiogram or MUGA

• Peripheral neuropathy NCI CTCAE grade = 1 or grade 2 if no pain on clinical examination

• Adequate hematological, liver and renal function:

Exclusion Criteria:

• Pregnant or lactating women

• Serious medical or psychiatric disorders that would interfere with the patient's safety or informed consent

• Clinically significant cardiovascular disease, requiring medication during the study and which might interfere with regularity of the study treatment, or not controlled by medication.

• Radiation of the target lesion within the last 4 weeks prior to randomization

• Prior radiation to = 30% of bone marrow

• Active bacterial, viral or fungal infection

• Known HCV infection

• Patients with clinically apparent brain metastases or evidence of a spinal cord compression

• Major surgery within 14 days before enrollment

• Systemic treatment, within 14 days before the first dose of ixazomib, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.

• Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial

• Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not

• History of other malignancy; patients who have been disease-free for 5 years or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible

• Prior treatment with a platinum derivative (except in (neo-)adjuvant setting if breast cancer recurrence did not occur within 12 months after (neo-)adjuvant chemotherapy completion) and/or with a proteasome inhibitor

• Known hypersensitivity to the study drugs

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Neoplasms
• Triple-Negative Breast Cancer

Intervention

Drug:
• Ixazomib
Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
• Carboplatin
Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.

Locations

Country	Name	City	State
Austria	Landeskrankenhaus Feldkirch, Innere Med. II, Interne E	Feldkirch	Vorarlberg
Austria	UK Graz: Universitätsklinik für Frauenheilkunde und Geburtshilfe, Klinische Abteilung für Gynäkologie	Graz
Austria	Universitätsklinik für Innere Medizin Graz	Graz	Steiermark
Austria	Universitätsklinik für Frauenheilkunde Innsbruck	Innsbruck	Tirol
Austria	LKH Hochsteiermark: Department für Hämato-Onkologie	Leoben
Austria	BHS Linz: Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie	Linz
Austria	KUK Linz: Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie	Linz
Austria	PMU Salzburg: Universitätsklinik für Innere Medizin III	Salzburg
Austria	Landeskrankenhaus Steyr, Innere Medizin II Onkologie	Steyr
Austria	AKH Wien Universitätsklinik für Frauenheilkunde: Klin. Abt. f. Allg. Gynäkologie und gynäkologische Onkologie	Vienna
Austria	Klinikum Kreuzschwestern Wels GmbH	Wels	Oberösterreich
Austria	LK Wiener Neustadt: Innere Medizin, Hämatologie und internistische Onkologie	Wiener Neustadt

Sponsors (2)

Lead Sponsor	Collaborator
Arbeitsgemeinschaft medikamentoese Tumortherapie	Takeda

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	Determination of maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs)	From treatment start until MTD (12 months --> start Phase II Q3 2017)
Secondary	Safety profile based on adverse events evaluation	Incidence, type, severity and consequences (e.g. study discontinuation) of an adverse event	During study treatment + 28 day after last study drug (approximately 3 years)
Secondary	Overall response rate		During study treatment every 8 weeks until progression + end of study treatment (approximately 3 years)
Secondary	Clinical benefit rate	Complete remission, partial remission or stable disease for at least 24 weeks	During study treatment every 8 weeks until progression + end of study treatment (approximately 3 years)
Secondary	Progression-free survival (PFS)		During study treatment every 8 weeks until progression + end of study treatment (approximately 3 years)
Secondary	Quality of Life of MBC patients	EORTC quality of life questionnaire (QLQ-C30 and QLQ-BR23)	Baseline + every 8 weeks until progression + at end of study treatment (approximately 3 years)